©2021, EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR ...
Zacks Investment Research on MSN
Editas Medicine (EDIT) reports Q4 loss, tops revenue estimates
Editas Medicine (EDIT) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.55 per share a year ago. These figures ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results